[go: up one dir, main page]

FR15C0003I1 - Production de muteines recombinantes du facteur de coagulation sanguine viii dans des lignees de cellules humaines - Google Patents

Production de muteines recombinantes du facteur de coagulation sanguine viii dans des lignees de cellules humaines

Info

Publication number
FR15C0003I1
FR15C0003I1 FR15C0003C FR15C0003I1 FR 15C0003 I1 FR15C0003 I1 FR 15C0003I1 FR 15C0003 C FR15C0003 C FR 15C0003C FR 15C0003 I1 FR15C0003 I1 FR 15C0003I1
Authority
FR
France
Prior art keywords
factor viii
human cell
production
muteins
factor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Octapharma Biopharmaceuticals GmbH
Original Assignee
Octapharma Biopharmaceuticals GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP00106225A external-priority patent/EP1136553A1/fr
Application filed by Octapharma Biopharmaceuticals GmbH filed Critical Octapharma Biopharmaceuticals GmbH
Publication of FR15C0003I1 publication Critical patent/FR15C0003I1/fr
Application granted granted Critical
Publication of FR15C0003I2 publication Critical patent/FR15C0003I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6437—Coagulation factor VIIa (3.4.21.21)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/647—Blood coagulation factors not provided for in a preceding group or according to more than one of the proceeding groups
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
FR15C0003C 2000-03-22 2015-01-20 Production de muteines recombinantes du facteur de coagulation sanguine viii dans des lignees de cellules humaines Active FR15C0003I2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP00106225A EP1136553A1 (fr) 2000-03-22 2000-03-22 Préparation de facteurs de la coagulation sanguine recombinants en lignées cellulaires humaines
US20324900P 2000-05-08 2000-05-08
PCT/EP2001/003220 WO2001070968A2 (fr) 2000-03-22 2001-03-21 Production de facteurs de coagulation sanguine recombines dans des lignees de cellules humaines
EP01927769A EP1266006B1 (fr) 2000-03-22 2001-03-21 Production de muteines recombinantes du facteur de coagulation sanguine viii dans des lignees de cellules humaines

Publications (2)

Publication Number Publication Date
FR15C0003I1 true FR15C0003I1 (fr) 2015-02-27
FR15C0003I2 FR15C0003I2 (fr) 2015-11-20

Family

ID=26070708

Family Applications (1)

Application Number Title Priority Date Filing Date
FR15C0003C Active FR15C0003I2 (fr) 2000-03-22 2015-01-20 Production de muteines recombinantes du facteur de coagulation sanguine viii dans des lignees de cellules humaines

Country Status (28)

Country Link
US (1) US7572619B2 (fr)
EP (2) EP1460131A3 (fr)
JP (1) JP3894795B2 (fr)
KR (1) KR100581574B1 (fr)
CN (1) CN1454257B (fr)
AT (1) ATE312176T1 (fr)
AU (3) AU5471501A (fr)
BE (1) BE2014C077I2 (fr)
BG (1) BG65930B1 (fr)
BR (1) BRPI0109494B8 (fr)
CA (1) CA2404163C (fr)
CZ (1) CZ303929B6 (fr)
DE (1) DE60115613T2 (fr)
DK (1) DK1266006T3 (fr)
EA (1) EA004317B1 (fr)
EE (1) EE200200538A (fr)
ES (1) ES2254403T3 (fr)
FR (1) FR15C0003I2 (fr)
HR (1) HRP20020767B1 (fr)
HU (1) HU228091B1 (fr)
IL (2) IL151857A0 (fr)
MX (1) MXPA02009221A (fr)
NO (1) NO330910B1 (fr)
NZ (1) NZ521732A (fr)
RS (1) RS50743B (fr)
SI (1) SI1266006T1 (fr)
SK (1) SK287706B6 (fr)
WO (1) WO2001070968A2 (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0109494B8 (pt) * 2000-03-22 2021-05-25 Octagene Gmbh muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii
PL206105B1 (pl) * 2000-09-19 2010-07-30 Emory Universityemory University Zmodyfikowany ludzki czynnik VIII oraz sposób modyfikacji ludzkiego czynnika VIII ze zmniejszeniem reaktywności na przeciwciało hamujące i zachowaniem aktywności prokoagulacyjnej
EP1469064A1 (fr) 2003-04-15 2004-10-20 DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH Expression des protéines dans des cellules endothéliales dérivées de cellules précurseurs du sang de cordon ombilical
ATE489105T1 (de) 2004-03-19 2010-12-15 Baxter Int Faktor ixa zur behandlung von blutungsstörungen
KR100624013B1 (ko) * 2004-06-25 2006-09-19 주식회사 녹십자홀딩스 동결건조된 알부민 비함유 재조합 사람 혈액응고 제 8인자 제제
EP1804839B1 (fr) 2004-09-22 2012-03-14 St. Jude Children's Research Hospital Expression améliorée du facteur ix dans les vecteurs de thérapie génique
US20060094104A1 (en) 2004-10-29 2006-05-04 Leopold Grillberger Animal protein-free media for cultivation of cells
JP5523674B2 (ja) * 2005-02-11 2014-06-18 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 植物タンパク質加水分解産物を含有する血清フリーの細胞培養液におけるポリペプチドの生産
EP1707634A1 (fr) 2005-03-29 2006-10-04 Octapharma AG Procédé pour l'isolation de protéines recombinantes
EP1739179A1 (fr) 2005-06-30 2007-01-03 Octapharma AG Transfection stable exempt de sérum et production des protéines recombinantes humaines dans des lignées cellulaires humaines
ES2440487T3 (es) 2006-07-13 2014-01-29 Wyeth Llc Producción de glucoproteínas
JP6050927B2 (ja) * 2007-04-26 2016-12-21 シーエヌジェイ ホールディングス，インコーポレイテッド 高シアル酸含量を有する組換えビタミンｋ依存性タンパク質およびその調製方法
WO2009028575A1 (fr) * 2007-08-27 2009-03-05 National University Corporation Nagoya University Activateur pour le promoteur du facteur vii de la coagulation du sang et son utilisation
CA2732423A1 (fr) 2008-08-21 2010-02-25 Octapharma Ag Facteurs humains viii et ix produits par recombinaison genetique
KR101722961B1 (ko) 2009-02-11 2017-04-04 알부메딕스 에이/에스 알부민 변이체 및 접합체
PT2482841T (pt) 2009-10-02 2019-03-01 Childrens Hospital Philadelphia A presente invenção refere-se à utilização de lactonas macrocíclicas para o tratamento da demodicose, em particular em cães.
US8748380B2 (en) 2009-10-30 2014-06-10 Novozymes Biopharma Dk A/S Albumin variants
US10233228B2 (en) 2010-04-09 2019-03-19 Albumedix Ltd Albumin derivatives and variants
BRPI1105317A2 (pt) * 2011-01-24 2013-04-30 Fundacco Hemoct De Ribeirco Preto produÇço estÁvel e em larga escala de fviii humano em linhagem celular humana sk-hep-1
SG192945A1 (en) 2011-02-25 2013-09-30 Chugai Pharmaceutical Co Ltd Fcgriib-specific fc antibody
CN102199607B (zh) * 2011-03-30 2012-11-14 山西大学 重组人凝血因子ix小基因及其ptc突变体稳定细胞株
KR101980164B1 (ko) 2011-05-13 2019-05-20 옥타파마 아게 재조합 ｆｖｉｉｉ의 생산에서 진핵 세포의 생산성을 증가시키는 방법
TW201307563A (zh) * 2011-05-19 2013-02-16 Shire Human Genetic Therapies 純化乙醯肝素－ｎ－硫酸酯酶之方法
CN102321668A (zh) * 2011-07-06 2012-01-18 中国人民解放军军事医学科学院野战输血研究所 一种表达重组人凝血因子ⅶ的方法及其专用载体
EP3939996A1 (fr) 2011-09-30 2022-01-19 Chugai Seiyaku Kabushiki Kaisha Molécule se liant à l'antigène favorisant la disparition des antigènes ayant une pluralité d'activités biologiques
CA2850579A1 (fr) 2011-10-18 2013-04-25 Carsten Horn Procede pour l'amelioration de la stabilite du facteur viii purifie apres la reconstitution
EP2780364A2 (fr) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Protéines ayant une demi-vie et d'autres propriétés améliorées
CN113416257A (zh) 2011-11-30 2021-09-21 中外制药株式会社 包含进入细胞内以形成免疫复合体的搬运体(载体)的药物
US9944691B2 (en) 2012-03-16 2018-04-17 Albumedix A/S Albumin variants
CA2862516C (fr) 2012-03-27 2023-02-14 Ngm Biopharmaceuticals, Inc. Compositions et methodes d'utilisation pour le traitement de troubles metaboliques
GB201210357D0 (en) * 2012-06-12 2012-07-25 Ucl Business Plc Factor VIII sequences
US8986991B2 (en) * 2012-07-03 2015-03-24 Expression Therapeutics, Llc High yield suspension cell line, system and method for making same
US10023628B2 (en) 2012-07-06 2018-07-17 Bioverativ Therapeutics Inc. Cell line expressing single chain factor VIII polypeptides and uses thereof
GB2512156A (en) 2012-11-08 2014-09-24 Novozymes Biopharma Dk As Albumin variants
EP2948168B1 (fr) * 2013-01-24 2018-07-18 Portola Pharmaceuticals, Inc. Inhibition d'inhibiteur de la voie du facteur tissulaire a l'aide de derives de facteur xa
CN105246914B (zh) 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
EP2853538A1 (fr) 2013-09-27 2015-04-01 Université Pierre et Marie Curie (Paris 6) Analogues de temporin-Sha et leurs utilisations
MD20170020A2 (ro) 2014-07-30 2017-07-31 Ngm Biopharmaceuticals, Inc. Compoziţii şi metode utilizate pentru tratamentul tulburărilor metabolice
SG11201702580PA (en) 2014-10-31 2017-05-30 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
PE20171111A1 (es) 2014-12-19 2017-08-07 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso
BR102015012334A2 (pt) 2015-05-27 2016-11-29 Fundação Hemoct De Ribeirão Preto Fundherp processo de produção do fator vii de coagulação sanguínea e fator vii de coagulação sanguínea
AR104956A1 (es) 2015-06-09 2017-08-30 Glycotope Gmbh MÉTODO MEJORADO PARA LA PRODUCCIÓN DE POLIPÉPTIDOS g-CARBOXILADOS
MX2018001825A (es) 2015-08-20 2018-05-07 Albumedix As Variantes y conjugados de albumina.
CN105219739A (zh) * 2015-09-21 2016-01-06 北京神源德生物科技有限公司 重组单纯疱疹病毒及它感染和制备它的宿主细胞以及它们的应用
EP3394098A4 (fr) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha Anticorps anti-myostatine et procédés d'utilisation
KR102450833B1 (ko) 2016-04-15 2022-10-05 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 혈우병 a 치료용 유전자 요법
CN109689099B (zh) 2016-08-05 2023-02-28 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
WO2018210771A1 (fr) 2017-05-17 2018-11-22 Octapharma Ag Procédé de production d'une protéine cible recombinante
US12084513B2 (en) 2017-11-14 2024-09-10 Chugai Seiyaku Kabushiki Kaisha Anti-C1S antibodies and methods of use
WO2020020364A1 (fr) * 2018-07-26 2020-01-30 正大天晴药业集团南京顺欣制药有限公司 Procédé de préparation d'un facteur viii de coagulation humain recombinant
GB201813528D0 (en) 2018-08-20 2018-10-03 Ucl Business Plc Factor IX encoding nucleotides
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides
JP2022512787A (ja) 2018-10-23 2022-02-07 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア 第ｖｉｉｉ因子機能を調節するための組成物および方法
WO2022259007A1 (fr) 2021-06-11 2022-12-15 Sorbonne Universite Peptides antimicrobiens courts

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL74909A (en) * 1984-04-20 1992-01-15 Genentech Inc Preparation of functional human factor viii and dna sequences,expression vectors,transformed microorganisms and cell lines used therein
JPS6171774A (ja) * 1984-09-14 1986-04-12 Sony Corp テレビジヨンカメラ装置のビ−ム電流制御装置
DE3684546D1 (de) * 1985-04-22 1992-04-30 Genetics Inst Herstellung mit hoher leistung des aktivfaktors ix.
JP2525022B2 (ja) * 1986-01-03 1996-08-14 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド ▲ＶＩＩＩ▼：ｃ因子型タンパク質の改良生産方法
US5451521A (en) * 1986-05-29 1995-09-19 Genetics Institute, Inc. Procoagulant proteins
US5422260A (en) * 1986-05-29 1995-06-06 Genetics Institute, Inc. -Legal Affairs Human factor VIII:c muteins
US5024939A (en) 1987-07-09 1991-06-18 Genentech, Inc. Transient expression system for producing recombinant protein
FR2638643B1 (fr) * 1988-11-09 1991-04-12 Transgene Sa Sequence d'adn codant pour le facteur ix humain ou une proteine analogue, vecteur d'expression, cellules transformees, procede de preparation du facteur ix et produits obtenus correspondants
KR927003812A (ko) * 1989-11-17 1992-12-18 노보 노르디스크 아크티에 셀스카브 인자 viii:c 활성을 갖는 단백질 복합체 및 그의 제조
SE465222C5 (sv) * 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
DE69101634D1 (de) 1990-01-26 1994-05-11 Immuno Ag Wien Rekombinant hergestellte blutfaktoren, verfahren zur exprimierung besagter blutfaktoren sowie in besagtem prozess verwendeter rekombinanter vaccina-virus.
US5445953A (en) * 1991-08-26 1995-08-29 Immuno Aktiengesellschaft Direct molecular cloning of a modified poxvirus genome
WO1994029471A1 (fr) * 1993-06-10 1994-12-22 Genetic Therapy, Inc. Vecteurs adenoviraux pour le traitement de l'hemophilie
EP0915975A2 (fr) * 1996-07-03 1999-05-19 Chiron Corporation Procedes d'administration d'excipients d'apport de genes recombines dans le traitement de l'hemophilie
US6114148C1 (en) * 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
JP2002517180A (ja) * 1997-12-05 2002-06-18 ジ・イミユーン・リスポンス・コーポレーシヨン 増大された発現を示す新規ベクターおよび遺伝子
US6358703B1 (en) * 1998-12-10 2002-03-19 Bayer Corporation Expression system for factor VIII
CA2362970A1 (fr) * 1999-02-19 2000-08-24 Octagene Gmbh Couples hormone-recepteur hormonal, constructions d'acides nucleiques, et utilisation de ceux-ci en therapie genique
AU6770200A (en) * 1999-08-13 2001-03-13 Fred Hutchinson Cancer Research Center Crystal of a truncated protein construct containing a coagulation factor viii c2domain in the presence or absence of a bound ligand and methods of use thereof
BRPI0109494B8 (pt) * 2000-03-22 2021-05-25 Octagene Gmbh muteína de fator viii, sequência de dna, vetor, processo para produção da muteína de fator viii, composição farmacêutica e uso da muteína do fator viii
WO2003009237A1 (fr) * 2001-07-18 2003-01-30 Skaginn Hf. Dispositif et procede pour l'etablissement d'un lien entre un operateur et des informations relatives a un objet traite par cet operateur

Also Published As

Publication number Publication date
CA2404163A1 (fr) 2001-09-27
HUP0300588A2 (hu) 2003-06-28
YU71002A (sh) 2005-11-28
EP1266006A2 (fr) 2002-12-18
IL151857A0 (en) 2003-04-10
AU5471501A (en) 2001-10-03
ATE312176T1 (de) 2005-12-15
DK1266006T3 (da) 2006-01-16
KR100581574B1 (ko) 2006-05-22
HU228091B1 (en) 2012-10-29
NO20024475L (no) 2002-11-20
BG107152A (bg) 2003-06-30
SK15042002A3 (sk) 2003-09-11
BG65930B1 (bg) 2010-05-31
CA2404163C (fr) 2009-09-29
US20040023333A1 (en) 2004-02-05
EA200201008A1 (ru) 2003-02-27
BRPI0109494B8 (pt) 2021-05-25
DE60115613T2 (de) 2006-08-24
CN1454257B (zh) 2013-01-16
EP1460131A2 (fr) 2004-09-22
SI1266006T1 (sl) 2006-06-30
JP2003530093A (ja) 2003-10-14
EA004317B1 (ru) 2004-02-26
AU2001254715B2 (en) 2006-02-02
US7572619B2 (en) 2009-08-11
CZ303929B6 (cs) 2013-07-03
DE60115613D1 (de) 2006-01-12
MXPA02009221A (es) 2005-07-25
EP1266006B1 (fr) 2005-12-07
SK287706B6 (en) 2011-07-06
IL151857A (en) 2010-05-31
HUP0300588A3 (en) 2005-09-28
FR15C0003I2 (fr) 2015-11-20
BE2014C077I2 (fr) 2020-01-30
NO330910B1 (no) 2011-08-15
RS50743B (sr) 2010-08-31
BR0109494A (pt) 2002-12-10
EE200200538A (et) 2004-04-15
WO2001070968A2 (fr) 2001-09-27
CN1454257A (zh) 2003-11-05
JP3894795B2 (ja) 2007-03-22
WO2001070968A3 (fr) 2001-12-13
KR20030011079A (ko) 2003-02-06
CZ20023166A3 (cs) 2003-02-12
NO20024475D0 (no) 2002-09-19
AU2006201848A1 (en) 2006-05-25
HRP20020767A2 (en) 2005-02-28
ES2254403T3 (es) 2006-06-16
NZ521732A (en) 2004-05-28
HRP20020767B1 (en) 2011-09-30
BRPI0109494B1 (pt) 2021-05-11
EP1460131A3 (fr) 2005-06-01

Similar Documents

Publication Publication Date Title
FR15C0003I2 (fr) Production de muteines recombinantes du facteur de coagulation sanguine viii dans des lignees de cellules humaines
ATE532858T1 (de) Menschliche gerinnungsfaktor-vii-polypeptide
RU2007105677A (ru) Модифицированные витамин к-зависимые полипептиды
ATE437221T1 (de) Lentivirale vektoren kodierend für gerinnungsfaktoren für die gentherapie
ATE320277T1 (de) Zusammensetzung und verfahren zur reparatur und regenerierung von knorpel und anderen geweben
ATE486614T1 (de) Zusammensetzungen zum einsatz in einer gentherapie zur behandlung von hämophilie
RU2002124123A (ru) Модифицированный фактор viii
ATE113475T1 (de) Hybride prokoagulierende proteine.
DE60143292D1 (de) Varianten des menschlichen Koagulationsfaktors VII
WO2007120457A3 (fr) Composition et procédé de stabilisation de tissu de la cornée après une chirurgie réfractive
ATE536405T1 (de) Hämatopoetische stammzellen und verfahren zur behandlung von neovaskulären augenerkrankungen damit
ATE513033T1 (de) Expression von proteinen in aus nabelschnurblut gewonnenen endothelzellen
JP2011506489A (ja) 止血をモジュレートする組成物およびその使用法
JP2006507328A (ja) フラビウイルス融合インヒビター
GB2451044A (en) Novel thrombolytic molecules and a process therefor
JP6991570B2 (ja) 分化誘導剤、分化誘導方法、および、これらに用いられる骨組織分解物の製造方法
JP3277227B2 (ja) 血液凝固阻害ペプチドの製造法
JP2774156B2 (ja) ヒトプロテインｃおよび／または活性化ヒトプロテインｃ様活性を有する蛋白
EP1679372A4 (fr) Nouveau polypeptide plexine, adn codant pour celui-ci et utilisation de celui-ci
Persson et al. Effects of Medin on Smooth Muscle Cells